MERS coronavirus: an emerging zoonotic virus
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFLA |
Texto Completo: | http://repositorio.ufla.br/jspui/handle/1/39405 |
Resumo: | Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus that was first reported in humans in June 2012 [1]. To date, MERS-CoV continues to infect humans with a fatality rate of ~35%. At least 27 countries have reported human infections with MERS-CoV (https://www.who.int/emergencies/mers-cov/en/). MERS-CoV is a zoonotic virus. Like severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV is believed to have originated from bats [2,3]. However, whereas the bat-to-human transmission of SARS-CoV was likely mediated by palm civets as intermediate hosts, humans likely acquired MERS-CoV from dromedary camels [4,5,6]. Human-to-human transmission of MERS-CoV does occur, but it is limited mostly to health care environments [7,8]. Moreover, whereas SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as a cellular receptor [9,10], MERS-CoV uses dipeptidyl peptidase 4 (DPP4) to enter target cells [11,12]. Currently, no vaccines or antiviral therapeutics have been approved for the prevention or treatment of MERS-CoV infection, although a number of them have been developed preclinically and/or tested clinically [13,14,15,16]. |
id |
UFLA_4c6f693fa16deaad5eb1f4f93b5ae216 |
---|---|
oai_identifier_str |
oai:localhost:1/39405 |
network_acronym_str |
UFLA |
network_name_str |
Repositório Institucional da UFLA |
repository_id_str |
|
spelling |
MERS coronavirus: an emerging zoonotic virusCoronavirusZoonotic virusSevere Acute Respiratory Syndrome (SARS)Vírus zoonóticoSíndrome respiratória aguda graveMiddle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus that was first reported in humans in June 2012 [1]. To date, MERS-CoV continues to infect humans with a fatality rate of ~35%. At least 27 countries have reported human infections with MERS-CoV (https://www.who.int/emergencies/mers-cov/en/). MERS-CoV is a zoonotic virus. Like severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV is believed to have originated from bats [2,3]. However, whereas the bat-to-human transmission of SARS-CoV was likely mediated by palm civets as intermediate hosts, humans likely acquired MERS-CoV from dromedary camels [4,5,6]. Human-to-human transmission of MERS-CoV does occur, but it is limited mostly to health care environments [7,8]. Moreover, whereas SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as a cellular receptor [9,10], MERS-CoV uses dipeptidyl peptidase 4 (DPP4) to enter target cells [11,12]. Currently, no vaccines or antiviral therapeutics have been approved for the prevention or treatment of MERS-CoV infection, although a number of them have been developed preclinically and/or tested clinically [13,14,15,16].MDPI2020-03-25T19:29:19Z2020-03-25T19:29:19Z2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfLI, F.; DU, L. MERS coronavirus: an emerging zoonotic virus. Viruses, [S. l.], v. 11, n. 7, 2019. DOI: https://doi.org/10.3390/v11070663.http://repositorio.ufla.br/jspui/handle/1/39405Virusesreponame:Repositório Institucional da UFLAinstname:Universidade Federal de Lavras (UFLA)instacron:UFLAAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessLi, FangDu, Lanyingeng2020-06-26T12:31:45Zoai:localhost:1/39405Repositório InstitucionalPUBhttp://repositorio.ufla.br/oai/requestnivaldo@ufla.br || repositorio.biblioteca@ufla.bropendoar:2020-06-26T12:31:45Repositório Institucional da UFLA - Universidade Federal de Lavras (UFLA)false |
dc.title.none.fl_str_mv |
MERS coronavirus: an emerging zoonotic virus |
title |
MERS coronavirus: an emerging zoonotic virus |
spellingShingle |
MERS coronavirus: an emerging zoonotic virus Li, Fang Coronavirus Zoonotic virus Severe Acute Respiratory Syndrome (SARS) Vírus zoonótico Síndrome respiratória aguda grave |
title_short |
MERS coronavirus: an emerging zoonotic virus |
title_full |
MERS coronavirus: an emerging zoonotic virus |
title_fullStr |
MERS coronavirus: an emerging zoonotic virus |
title_full_unstemmed |
MERS coronavirus: an emerging zoonotic virus |
title_sort |
MERS coronavirus: an emerging zoonotic virus |
author |
Li, Fang |
author_facet |
Li, Fang Du, Lanying |
author_role |
author |
author2 |
Du, Lanying |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Li, Fang Du, Lanying |
dc.subject.por.fl_str_mv |
Coronavirus Zoonotic virus Severe Acute Respiratory Syndrome (SARS) Vírus zoonótico Síndrome respiratória aguda grave |
topic |
Coronavirus Zoonotic virus Severe Acute Respiratory Syndrome (SARS) Vírus zoonótico Síndrome respiratória aguda grave |
description |
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus that was first reported in humans in June 2012 [1]. To date, MERS-CoV continues to infect humans with a fatality rate of ~35%. At least 27 countries have reported human infections with MERS-CoV (https://www.who.int/emergencies/mers-cov/en/). MERS-CoV is a zoonotic virus. Like severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV is believed to have originated from bats [2,3]. However, whereas the bat-to-human transmission of SARS-CoV was likely mediated by palm civets as intermediate hosts, humans likely acquired MERS-CoV from dromedary camels [4,5,6]. Human-to-human transmission of MERS-CoV does occur, but it is limited mostly to health care environments [7,8]. Moreover, whereas SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as a cellular receptor [9,10], MERS-CoV uses dipeptidyl peptidase 4 (DPP4) to enter target cells [11,12]. Currently, no vaccines or antiviral therapeutics have been approved for the prevention or treatment of MERS-CoV infection, although a number of them have been developed preclinically and/or tested clinically [13,14,15,16]. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019 2020-03-25T19:29:19Z 2020-03-25T19:29:19Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
LI, F.; DU, L. MERS coronavirus: an emerging zoonotic virus. Viruses, [S. l.], v. 11, n. 7, 2019. DOI: https://doi.org/10.3390/v11070663. http://repositorio.ufla.br/jspui/handle/1/39405 |
identifier_str_mv |
LI, F.; DU, L. MERS coronavirus: an emerging zoonotic virus. Viruses, [S. l.], v. 11, n. 7, 2019. DOI: https://doi.org/10.3390/v11070663. |
url |
http://repositorio.ufla.br/jspui/handle/1/39405 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
Viruses reponame:Repositório Institucional da UFLA instname:Universidade Federal de Lavras (UFLA) instacron:UFLA |
instname_str |
Universidade Federal de Lavras (UFLA) |
instacron_str |
UFLA |
institution |
UFLA |
reponame_str |
Repositório Institucional da UFLA |
collection |
Repositório Institucional da UFLA |
repository.name.fl_str_mv |
Repositório Institucional da UFLA - Universidade Federal de Lavras (UFLA) |
repository.mail.fl_str_mv |
nivaldo@ufla.br || repositorio.biblioteca@ufla.br |
_version_ |
1815439370213130240 |